1. Does Serum Urate Change as Parkinson’s Disease Progresses?
- Author
-
Xiqun Chen, Rachit Bakshi, Eric A. Macklin, Yasemin G Hasimoglu, and Michael A. Schwarzschild
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Parkinson's disease ,Short Communication ,Disease ,Severity of Illness Index ,Gastroenterology ,Part iii ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,disease progression ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Longitudinal Studies ,Stage (cooking) ,Aged ,Dopamine Plasma Membrane Transport Proteins ,business.industry ,Disease progression ,longitudinal study ,Parkinson Disease ,Middle Aged ,medicine.disease ,Corpus Striatum ,Uric Acid ,Serum urate ,030104 developmental biology ,Parkinson’s disease ,urate ,Biomarker (medicine) ,Female ,Neurology (clinical) ,business ,Biomarkers ,030217 neurology & neurosurgery - Abstract
Higher serum urate concentration is associated with decreased risk of Parkinson’s disease (PD) as well as slower disease progression, but its relationship with severity of PD remains unclear. This study investigated whether changes in serum urate concentration over 5 years were associated with disease progression assessed by MDS-UPDRS Part III score, Hoehn and Yahr stage, or DaTscan imaging. Average serum urate concentration was stable over time and change in serum urate concentration did not correlate with worsening of measures of PD progression. These results suggest that serum urate concentration is not a monitoring biomarker of PD progression in early stages.
- Published
- 2020
- Full Text
- View/download PDF